Hepatic failure associated with immune checkpoint inhibitors: An analysis of the Food and Drug Administration Adverse Event Reporting System database
Cancer Medicine · 2023
DOI: 10.1002/cam4.5655 ↗At a glance
Journal article in Cancer Medicine, 2023. Written by Ye Xu and 5 co-authors. Institution: Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Major MEDLINE topics: Antineoplastic Agents, Immunological, Liver Failure. Cited 11 times so far (Crossref); 28 references. The full text is freely available (open access, CC BY 4.0). Funded by: Beijing Science and Technology Planning Project, Beijing Hospital Authority.
Abstract (original language)
Background
Hepatic failure induced by immune checkpoint inhibitors (ICIs) has been reported in only a few case series and case reports.
Objective
We aimed to explore the association between ICIs and hepatic failure and characterize the clinical features of ICI‐associated hepatic failure in the pharmacovigilance database.
Methods
Data from the first quarter (Q1) of 2015 to the fourth quarter (Q4) of 2021 in the US Food and Drug Administration Adverse Event Reporting System (FAERS) database were retrieved for disproportionality and Bayesian analysis. Reporting odds ratios (ROR) and information component (IC) were used to evaluate correlations between ICIs and hepatic failure.
Results
Hepatic failure occurred in 0.19% (18,454/9,647,655) of all cases in the FAERS database, of which 654 cases were associated with ICIs. The overall median time from ICIs initiation to hepatic failure onset was 38 days, 72.3% of the adverse events occurred within the first 3 months, and 68.65% of the cases died after developing hepatic failure. In general, a strong signal was shown between ICIs and hepatic failure (ROR 025 = 2.70, IC 025 = 1.39). For the three categories of ICIs, programmed cell death 1 ligand 1 inhibitors (ROR 025 = 3.09, IC 025 = 1.57) had a higher risk signal than programmed cell death protein 1 inhibitors and cytotoxic T lymphocyte‐associated protein 4 inhibitors. For monotherapy, atezolizumab showed the strongest risk signal (ROR 025 = 4.07, IC 025 = 1.90). The combination of nivolumab and ipilimumab showed stronger signals of hepatic failure compared with nivolumab or ipilimumab alone (nivolumab + ipilimumab vs. ipilimumab: ROR 025 = 1.40, IC 025 = 0.16; nivolumab + ipilimumab vs. nivolumab: ROR 025 = 1.24, IC 025 = 0.34). Considering the concomitant agents used with ICIs, the majority of these regimens showed stronger signals than ICI monotherapy, such as acetaminophen (ICIs + acetaminophen vs. ICIs: ROR 025 = 1.06, IC 025 = 0.32).
Conclusions
ICIs had possible strong signals associated with hepatic failure, and most cases of hepatic failure occurred within the first 3 months and had poor outcomes, which should attract clinical attention.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
- School of Pharmacy, Capital Medical University, Beijing, China.
- School of Automation Science and Electrical Engineering, Beihang University, Beijing, China.
ORCID profiles: Xiangli Cui
Funding
- Beijing Science and Technology Planning Project
- Beijing Hospital Authority
Cite
APA
Xu, Y., Yan, C., Zhao, Y., Li, D., Guo, M., & Cui, X. (2023). Hepatic failure associated with immune checkpoint inhibitors: An analysis of the Food and Drug Administration Adverse Event Reporting System database. Cancer Medicine. https://doi.org/10.1002/cam4.5655
Vancouver
Xu Y, Yan C, Zhao Y, Li D, Guo M, Cui X. Hepatic failure associated with immune checkpoint inhibitors: An analysis of the Food and Drug Administration Adverse Event Reporting System database. Cancer Medicine. 2023. doi:10.1002/cam4.5655
BibTeX
@article{Xu2023,
author = {Xu, Ye and Yan, Cilin and Zhao, Ying and Li, Dandan and Guo, Mingxing and Cui, Xiangli},
title = {Hepatic failure associated with immune checkpoint inhibitors: An analysis of the Food and Drug Administration Adverse Event Reporting System database},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.5655}
}
EUVIMED